| Menopausal syndrome

Estrogel vs Bijuva

Side-by-side clinical, coverage, and cost comparison for menopausal syndrome.

Deep comparison between: Estrogel vs Bijuva with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsBijuva has a higher rate of injection site reactions vs Estrogel based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Bijuva but not Estrogel, including UnitedHealthcare

Category

Estrogel

Bijuva

At A Glance

RouteTopical

FrequencyDaily

ClassEstrogen

RouteOral

FrequencyDaily

ClassEstrogen-progesterone combination

Indications

Menopausal syndrome
Postmenopausal atrophic vaginitis

Menopausal syndrome

Dosing

Menopausal syndrome, Postmenopausal atrophic vaginitis EstroGel 0.06% 1.25 g (0.75 mg estradiol) once daily applied as a thin layer over the entire arm on the inside and outside from wrist to shoulder.

Menopausal syndrome Start with 0.5 mg estradiol/100 mg progesterone orally once each evening with food; adjust dose based on clinical response; attempt to taper or discontinue at 3 to 6 month intervals.

Contraindications

Abnormal genital bleeding of unknown etiology
Current or history of breast cancer
Current or history of estrogen-dependent neoplasia
Active DVT, PE, or history of these conditions
Active arterial thromboembolic disease (e.g., stroke or MI), or history of these conditions
Known anaphylactic reaction, angioedema, or hypersensitivity to EstroGel or any excipient
Hepatic impairment or disease
Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders

Abnormal genital bleeding of unknown etiology
Breast cancer or history of breast cancer
Estrogen-dependent neoplasia
Active deep vein thrombosis (DVT), pulmonary embolism (PE), or history of these conditions
Active arterial thromboembolic disease (stroke, myocardial infarction) or history of these conditions
Known anaphylactic reaction, angioedema, or hypersensitivity to BIJUVA
Hepatic impairment or disease
Known thrombophilic disorders, such as protein C, protein S, or antithrombin deficiency

Drug Interactions

1224View drug interactions

2383View drug interactions

Adverse Reactions

Most common (>=5%) Breast pain, headache, flatulence

Serious Cardiovascular disorders, malignant neoplasms

Postmarketing Endometrial cancer, breast cancer, deep vein thrombosis, myocardial ischemia, phlebitis, nausea, alopecia, rash, retinal vein occlusion, meningioma, angioedema, hepatitis

Most common (>=3%) Breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge, pelvic pain

Serious Cardiovascular disorders, malignant neoplasms

Postmarketing Abdominal pain, abdominal distention, diarrhea, vomiting, fatigue, malaise, weight increased, fluid retention, muscle spasms, pain in extremity, dizziness, somnolence, insomnia, sleep disorder, breast pain, uterine bleeding, night sweats, pruritus, hot flush

Pharmacology

Estradiol is the principal intracellular human estrogen, acting through binding to nuclear receptors in estrogen-responsive tissues; it modulates pituitary gonadotropin secretion via a negative feedback mechanism to reduce elevated LH and FSH levels seen in postmenopausal women.

Estrogen-progesterone combination; estradiol binds nuclear estrogen receptors to reduce elevated gonadotropin levels and maintain secondary sexual characteristics in postmenopausal women, while progesterone binds progesterone receptors to transform proliferative endometrium into secretory endometrium and oppose estrogen actions.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Estrogel